摘要
膀胱癌治疗,即全身治疗,在过去的三十年中,由于没有比化疗更新的治疗方案,其占据了主导地位。无论化疗本身是在第一还是第二线,在不可忽视的毒性的代价下,它的可能性似乎都已经取得了适中的停滞期。靶向治疗,改变了许多不同肿瘤的治疗,在膀胱癌中似乎是无效的。最近,一种基于养生学上的新一代的免疫疗法代表了未来系统治疗膀胱癌的最有前景的道路。检查点抑制剂,即PD1 / PD-L1通路抑制,在许多其他类型的肿瘤中表现出令人印象深刻的结果,有望成为治疗膀胱癌的主要参与者。其他免疫治疗策略如融合蛋白虽然还很遥远,但十分的有前途,如下是一个简短的膀胱癌免疫治疗现状的综述。
关键词: 膀胱癌;临床试验;免疫治疗;尿路上皮癌。
图形摘要
Current Drug Targets
Title:Emerging Immunotargets in Bladder Cancer
Volume: 17 Issue: 7
Author(s): Francesco Massari, Chiara Ciccarese, Nuno Vau, Matteo Santoni, Rodolfo Montironi, Liang Cheng, Rita C. Marques and Marina Scarpelli, Jorge Fonseca, Marc R Matrana, Moch Holger, Stefano Cascinu, Giampaolo Tortora, Antonio Lopez-Beltran
Affiliation:
关键词: 膀胱癌;临床试验;免疫治疗;尿路上皮癌。
摘要: Bladder cancer treatment, namely systemic therapy, was dominated in the last three decades due to the absence of newer therapeutic options other than chemotherapy regimens. Chemotherapy, by itself, both in first and second-line seems to have achieved the modest plateau of its possibilities at the cost of non-negligible toxicity. Targeted therapies, which changed the therapy of many different tumors, seem rather ineffective in bladder cancer. More recently, a new generation of Immunotherapy based regimens represent the most promising avenue for the future systemic treatment of bladder cancer. Checkpoint inhibition, namely PD1/PD-L1 pathway inhibition, showed impressive results in many other tumor types and are expected to become a major player in the treatment of bladder cancer. Other immunotherapy strategies such as fusion proteins represent distant, although promising, options. A brief overview of the current status of bladder cancer immunotherapy is presented.
Export Options
About this article
Cite this article as:
Francesco Massari, Chiara Ciccarese, Nuno Vau, Matteo Santoni, Rodolfo Montironi, Liang Cheng, Rita C. Marques and Marina Scarpelli, Jorge Fonseca, Marc R Matrana, Moch Holger, Stefano Cascinu, Giampaolo Tortora, Antonio Lopez-Beltran , Emerging Immunotargets in Bladder Cancer, Current Drug Targets 2016; 17 (7) . https://dx.doi.org/10.2174/1389450117666160201105537
DOI https://dx.doi.org/10.2174/1389450117666160201105537 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Carbohydrate-Metal Complexes and their Potential as Anticancer Agents
Current Medicinal Chemistry The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine Vitamin D Receptor Agonists, Cancer and the Immune System: An Intricate Relationship
Current Topics in Medicinal Chemistry Physico-chemical and Biological Evaluation of Flavonols: Fisetin, Quercetin and Kaempferol Alone and Incorporated in beta Cyclodextrins
Anti-Cancer Agents in Medicinal Chemistry Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design Sesamol: An Efficient Antioxidant with Potential Therapeutic Benefits
Medicinal Chemistry Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions
Current Medicinal Chemistry Contemporary Overview on Clinical Trials and Future Prospects of Hepato-protective Herbal Medicines
Reviews on Recent Clinical Trials Immune Response and Immunotherapy: Live Attenuated Listeria monocytogenes (Lm)-LLO Immunotherapy for the Treatment of Prostate Cancer
Current Cancer Therapy Reviews Vesicovaginal Fistula
Current Women`s Health Reviews Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism Phytochemical and Biological Activities of an Anticancer Plant Medicine: Brucea javanica
Anti-Cancer Agents in Medicinal Chemistry HSP60 as a Drug Target
Current Pharmaceutical Design MicroRNAs: A Novel Non-Invasive Biomarker for Patients with Urological Malignancies
Current Pharmaceutical Biotechnology Network Propagation Reveals Novel Features Predicting Drug Response of Cancer Cell Lines
Current Bioinformatics Current Uses of Robotic Surgery for the Treatment of Benign Adnexal Conditions
Current Women`s Health Reviews Pharmacometrics in Dose Finding or Dose Optimization of Anti-Retroviral and Anti-Tubercular Drugs
Infectious Disorders - Drug Targets Targeted Nanostructured Lipid Carriers for Delivery of Paclitaxel to Cancer Cells: Preparation, Characterization, and Cell Toxicity
Current Drug Delivery